Ranbaxy Q4 net loss declines sharply to Rs 158.48 crore

Pharma major Ranbaxy Laboratories today reported a drastic drop in net loss at Rs 158.48 crore during the fourth quarter ended December 31, 2013.

The company had posted a net loss of Rs 492.44 crore in the corresponding quarter of the last financial year (2012-13), Ranbaxy said in a regulatory filing to the stock exchanges.

It had recorded a net loss of Rs 454.16 crore in Q3 of this fiscal.

Total income from operations of the company rose to Rs 2,893.99 crore from Rs 2,711.21 crore during the same period last year.

Earlier this month, Ranbaxy Laboratories signed an agreement with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis.

The product will be introduced in India and other emerging markets soon, the company had said.

Shares of the company were trading at Rs 328.70, up 2.16 per cent on the BSE.

EDITORIAL OF THE DAY

  • Reservations, along with economic subsidies, must go to get India moving

    A young man, in his early twenties, starts an agitation demanding reservation for the community he represents.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

The China story isn’t over yet

China’s financial markets are currently in the eye of a ...

Anuja Sharma

Love yourself to love others

“There are two basic motivating forces: fear and love. When ...

Gautam Gupta

It's a 'blog eat blog' world out there

Let me tell you, fashion journalism has truly taken the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture